title: Inhibiting the onset of lactation. Is cabergoline an alternative to bromocriptine?
abstract: In late 2014, following a review by the French Health Products Agency (ANSM) and the European Pharmacovigilance Risk Assessment Committee (PRAC), the European Commission restricted the indications for bromocriptine in lactation inhibition to situations in which breastfeeding must be stopped for medical reasons. Some healthcare professionals have asked us whether bromocriptine can be replaced with cabergoline, an option that is already used in practice and authorised in some European countries.
mesh_terms: D001971:Bromocriptine / Q000009:adverse effects / Q000627:therapeutic use*; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000009:adverse effects / Q000627:therapeutic use; D004873:Ergolines / Q000009:adverse effects / Q000627:therapeutic use*; D005060:Europe; D005260:Female; D005602:France; D006801:Humans; D007774:Lactation / Q000187:drug effects*
chemical_list: D018491:Dopamine Agonists; D004873:Ergolines; D001971:Bromocriptine; D000077465:Cabergoline